Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1061 | 999 | 1121 | 1010 | 1157 | 1387 |
Fund Return | 6.05% | -0.11% | 12.11% | 0.32% | 2.96% | 3.33% |
Place in category | 189 | 360 | 309 | 244 | 160 | 101 |
% in Category | 33 | 62 | 53 | 55 | 38 | 33 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU1923635863 | 2.92B | 11.18 | -8.80 | - | ||
LU2000522420 | 2.92B | 7.05 | -13.84 | - | ||
UBSLuxEqSICAV USA Growth H FAcc | 2.88B | 22.48 | 3.78 | 12.51 | ||
LU0508198768 | 2.88B | 21.94 | 3.24 | 11.94 | ||
LU0511785726 | 2.88B | 20.90 | 2.19 | 10.80 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU2258443139 | 2.36B | 7.69 | 0.87 | - | ||
NN L Patrimonial Balanced Europeane | 694.32M | 5.53 | -1.30 | 3.85 | ||
LU1444115874 | 694.32M | 5.67 | -1.03 | 4.00 | ||
NN L Patrimonial Balanced Europeanp | 694.32M | 5.53 | -1.29 | 3.85 | ||
LU1744628287 | 505.91M | 6.58 | -1.57 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UBS (Lux) BFConvert Eurp EUR U-X EUR Inc | LU0415180149 | 18.75 | - | - | |
UBS Lux Equity SICAV - European Opportunity Uncons | LU0549584711 | 18.34 | 42,753.980 | +1.42% | |
UBS(LUX) ES Eurp Hi DivSsEUR U-X-acc | LU0566497789 | 14.58 | - | - | |
UBS Lux Bond SICAV - Convert Global EUR I-X-dist | LU0396332644 | 14.46 | 186.220 | +0.32% | |
Teva Pharmaceutical Finance Netherlands II B.V 7.375% | XS2592804434 | 0.63 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review